The global obesity epidemic has resulted in significant morbidity and mortality. However, the
medical treatment of obesity is limited. Gastric bypass is an effective surgical treatment but …

Recent insights into the neural circuits controlling energy balance and glucose homeostasis
have rekindled the hope for development of novel treatments for obesity and diabetes …

Strategy for intention to treat analysis in randomised trials with missing outcome data | The BMJ
Skip to main content Intended for healthcare professionals Access provided by Google Indexer …

ABSTRACT The American Association of Clinical Endocrinologists/American College of
Endocrinology Medical Guidelines for Clinical Practice are systematically developed …

Central glucagon-like-peptide-1 (GLP-1) receptor activation reduces food intake; however,
brain nuclei and mechanism (s) mediating this effect remain poorly understood. Although …

The long-acting glucagon-like peptide-1 receptor (GLP-1R) agonists, exendin-4 and
liraglutide, suppress food intake and body weight. The mediating site (s) of action for the …

We studied interscapular brown adipose tissue (iBAT) activity in wild-type (WT) and
glucagon-like peptide 1 receptor (GLP-1R)–deficient mice after the administration of the …

OBJECTIVE To assess the effects of exenatide on body weight and glucose tolerance in
nondiabetic obese subjects with normal or impaired glucose tolerance (IGT) or impaired …

Aims New drugs for type 2 diabetes need to demonstrate their cardiovascular safety, due
regulatory requirements from the Food and Drug Administration. For this reason, glucagon …

Context: Appetite-related hormones may play an important role in weight regain after obesity
therapy. Objective: Our objective was to investigate the potential involvement of ghrelin …